Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

Haematologica

Volumn 97, Issue 9, 2012, Pages 1348-1356

  Garg, Tarun K ^a   Szmania, Susann M ^a   Khan, Junaid A ^a   Hoering, Antje ^b   Malbrough, Paul A ^a   Moreno Bost, Amberly ^a   Greenway, Amy D ^a   Lingo, Joshuah D ^a   Li, Xin ^a   Yaccoby, Shmuel ^a   Suva, Larry J ^c   Storrie, Brian ^c   Tricot, Guido ^d   Campana, Dario ^e   Shaughnessy, John D ^a   Nair, Bijay P ^a   Bellamy, William T ^c   Epstein, Joshua ^a   Barlogie, Bart ^a   van Rhee, Frits ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Expansion; Myeloma; Natural killer cells

Indexed keywords

CD137 LIGAND; DNAX ACCESSORY MOLECULE 1; IMMUNOGLOBULIN G; INTERLEUKIN 15; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; UNCLASSIFIED DRUG; INTERLEUKIN 2 RECEPTOR GAMMA; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL EXPANSION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE HOMING; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; OSTEOLYSIS; PHENOTYPE; ANIMAL; APOPTOSIS; CELL PROLIFERATION; ENZYME IMMUNOASSAY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE; T LYMPHOCYTE; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; INTERLEUKIN-2; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OSTEOLYSIS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 84865841809     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.056747     Document Type: Article

References (34)

1. van Rhee F, Anaissie E, Angtuaco E, Bartel TB, Epstein J, Nair B, et al. Myeloma. In: Lichtman MA, Beutler E, Kipps T, Seligsohn U, Kaushansky K, Prchal J, eds. Williams Hematology. New York: McGraw-Hill Medical, 2010:1645-81.
2. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-84.
3. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-9.
4. Purdy AK, Campbell KS. Natural killer cells and cancer: regulation by the killer cell Iglike receptors (KIR). Cancer Biol Ther. 2009;8(23):2211-20.
5. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002;100(6): 1935-47.
6. McQueen KL, Parham P. Variable receptors controlling activation and inhibition of NK cells. Curr Opin Immunol. 2002;14(5):615-21.
7. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-100.
8. Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev. 2006;214:202-18.
9. Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, et al. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Br J Haematol. 2008;143(5):641-53.
10. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69(9): 4010-7.
11. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S, et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin-and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol. 1996;156(10):3678-86.
12. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92(8):2908-13.
13. Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol. 2009;84(1):6-14.
14. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology. 2004;145(1):401-6.
15. Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E, et al. CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia. 2005;19(5):835-40.
16. Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11(3):341-55.
17. Carlens S, Gilljam M, Chambers BJ, Aschan J, Guven H, Ljunggren HG, et al. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol. 2001;62(10):1092-8.
18. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111(6):3155-62.
19. Voskens CJ, Watanabe R, Rollins S, Campana D, Hasumi K, Mann DL. Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res. 2010;29:134-46.
20. Fujisaki H, Kakuda H, Imai C, Mullighan CG, Campana D. Replicative potential of human natural killer cells. Br J Haematol. 2009;145(5):606-13.
21. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev. 2006;214:73-91.
22. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107(1):159-66.
23. Miller J. Should natural killer cells be expanded in vivo or ex vivo to maximize their therapeutic potential? Cytotherapy. 2009;11(3):259-60.
24. Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114(13):2667-77.
25. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376-83.
26. Uherek C, Tonn T, Uherek B, Becker S, Schnierle B, Klingemann HG, et al. Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood. 2002;100(4):1265-73.
27. Schirrmann T, Pecher G. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res. 2005;29(3):301-6.
28. Demirtzoglou FJ, S. P, G. Z. Cytolytic and cytotoxic activity of a human natural killer cell line genetically modified to specifically recognize HER-2/neu overexpressing tumor cells. Immunopharmacol Immunotoxicol. 2006;28:571-90.
29. Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC, et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood. 2009;114(12):2417-26.
30. Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood. 2008;111(3):1309-17.
31. Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol. 2008;180(1):163-70.
32. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009;113(15):3503-11.
33. Lundqvist A, Abrams SI, Schrump DS, Alvarez G, Suffredini D, Berg M, et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006;66 (14):7317-25.
34. Lapteva N, Sun J, Durrett A, Vera J, Jackson K, Szmania S, et al. Robust ex vivo expansion of natural killer cells for clinical applications in gas-permable rapid expansion cell culture devices. Cytotherapy. 2011;13: Abstract 207.